Relievant Medsystems Announces Release of ASPN Guidelines for the Diagnosis and Treatment of Vertebrogenic Low Back Pain by Basivertebral Nerve Ablation


Relieving Medsystems, Inc.

Published guidelines with the highest evidence rating give physicians the confidence to adopt basivertebral nerve ablation as first-line treatment

MINNEAPOLIS, Sept. 20, 2022 (GLOBE NEWSWIRE) — Relievant Medsystems, a company focused on transforming the diagnosis and treatment of vertebral pain, a type of chronic low back pain (CLBP), today announced that the American Society of Pain & Neuroscience (ASPN) multidisciplinary working group of leading experts have assigned a grade A evidence rating for basivertebral nerve (BVN) ablation and developed best practice guidelines for the diagnosis and treatment of vertebrogenic pain with ablation of the BVN. Best practice guidelines are now published in the Journal of Pain Research.

Following the publication of these guidelines, physicians can confidently recommend BVN ablation as the first treatment for patients with anterior spine pain and Modic* changes after six months of unsuccessful conservative care. Based on US Preventive Services Task Force (USPSTF) definitions, an A rating indicates high certainty that the net benefit is substantial in appropriately selected individuals.

“With strong clinical evidence, including two level I randomized controlled trials and long-term data supporting the efficacy and safety of BVN ablation, this treatment option has played an increasingly important role. in the approach to the treatment of chronic vertebrogenic low back pain over the past few years,” said Professor Dawood Sayed MD, lead author of the ASPN Best Practice Guidelines, Anesthetist and Head of Pain Medicine at Health System from the University of Kansas. “The ASPN Best Practice Guidelines reflect a marked change in the way we treat and provide lasting, life-changing improvement to patients with chronic vertebrogenic low back pain.”

For more information on the ASPN’s BVN Best Practice Guidelines, register for a live webinar at 7:30 p.m. CT September 20 presented by the authors of the post.

Relievant Medsystems’ Intracept minimally invasive procedure is the only FDA cleared treatment for chronic vertebrogenic low back pain. The technology uses targeted radiofrequency energy to block the basivertebral nerve from transmitting pain signals to the brain. The procedure usually takes place at an outpatient surgery center and takes about an hour. Based on existing data, patients experience minimal post-operative pain and generally rapid recovery times. Patients often experience pain relief within two weeks of treatment with the Intracept procedure.

“It is a historic day for the patients and physicians we serve to have published guidelines from a multidisciplinary society giving physicians a simple and actionable pathway to not only diagnose vertebrogenic pain, but also to integrate ablation BVN as the first treatment for patients who meet the criteria noted in the guidelines,” said Tyler Binney, President and CEO of Relievant Medsystems. “The Intracept procedure has changed the lives of patients with chronic vertebrogenic low back pain, and we are thrilled that these guidelines provide additional evidence-based support to physicians and ultimately expand patient access to this groundbreaking technology.

*Modic Type 1 and/or Modic Type 2 changes on MRI

About vertebrogenic pain
Of the 30 million people in the United States with chronic low back pain, 1 in 6 are likely to experience vertebrogenic pain, which is a distinct type of chronic low back pain caused by damage to the endplates, the interface between the disc and the spinal cord. vertebral body. . Patients usually have pain in the middle of the lower back, which gets worse when they bend over, sit for long periods of time, or when they are active. A doctor can confirm that a patient’s pain is vertebrogenic by observing changes in Modic, a biomarker seen on standard MRI that indicates inflammation at the spinal plate.

About Relievant Medsystems
Relievant Medsystems is a commercial-stage medical device company that is transforming the diagnosis and treatment of vertebral pain, a form of chronic low back pain (CLBP), with the Intracept procedure – a new, clinically proven, commercially available treatment designed to improve quality of life for millions of indicated patients. For more information about Relievant Medsystems and the Intracept procedure, visit

Media Contact:
Shelli Lissick, Bellmont Partners
(651) 276-6922 | [email protected]

Investor contacts:
Marissa Bych, Gilmartin Group
(805) 305-1244 | [email protected]


Comments are closed.